Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Sep;58(9):1634-41.
doi: 10.1111/j.1532-5415.2010.03021.x.

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

Kenneth E Schmader  1 , Gary R Johnson, Patricia Saddier, Maria Ciarleglio, William W B Wang, Jane H Zhang, Ivan S F Chan, Shing-Shing Yeh, Myron J Levin, Ruth M Harbecke, Michael N Oxman; Shingles Prevention Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

Kenneth E Schmader et al. J Am Geriatr Soc. 2010 Sep.

Abstract

Objective: To determine the efficacy of a zoster vaccine on herpes zoster (HR)-related interference with activities of daily living (ADLs) and health-related quality of life (HRQL).

Design: Randomized double-blind placebo controlled trial.

Setting: Twenty-two U.S. sites.

Participants: Thirty eight thousand five hundred forty-six women and men aged 60 and olcer.

Measurements: HZ burden of interference with ADLs and HRQL using ratings from the Zoster Brief Pain Inventory (ZBPI) and Medical Outcomes Study 12-item Short Form Survey (SF-12) mental component summary (MCS) and physical component summary (PCS) scores. Vaccine efficacy was calculated for the modified-intention-to-treat trial population and solely in participants who developed HZ.

Results: For the modified-intention-to-treat population, the overall zoster vaccine efficacy was 66% (95% confidence interval (CI)=55-74%) for ZBPI ADL burden of interference score and 55% (95% CI=48-61%) for both the SF-12 MCS and PCS scores. Of participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of interference score by 31% (95% CI=12-51%) and did not significantly reduce the effect on HRQL.

Conclusions: Zoster vaccine reduced the burden of HZ-related interference with ADLs in the population of vaccinees and in vaccinees who developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population of vaccinees but not in vaccinees who developed HZ.

PubMed Disclaimer

Conflict of interest statement

Kenneth E. Schmader: Grants, including Shingles Prevention Study, consultant

Gary R. Johnson: No conflicts

Patricia Saddier: Employee

Maria Ciarleglio: No conflicts

William W.B. Wang: Employee

Jane H. Zhang: No conflicts

Ivan S.F. Chan: Employee

Shing-Shing Yeh: No conflicts, Shingles Prevention Study only

Myron J. Levin: Grants including Shingles Prevention Study, consultant, patent

Ruth M. Harbecke: No conflicts; Shingles Prevention Study only

Michael N. Oxman: No conflicts; Shingles Prevention Study only

Conflict of Interest:

This study was conducted by the Cooperative Studies Program of the Department of Veterans Affairs in collaboration with the NIAID, National Institutes of Health and Merck & Co. Inc. Funding was provided by the Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development and by a grant from Merck & Co., Inc. to the VA Cooperative Studies Program.

Figures

Figure 1
Figure 1
Zoster Vaccine Efficacy (%) in All Subjects (modified intention to treat analysis, n = 38,501). The figure shows zoster vaccine efficacy for Herpes Zoster Pain and Discomfort Burden of Illness (HZ BOI) Score (61%, 95% CI: 51, 69); Zoster Brief Pain Inventory ADL Burden of Interference Score (ZBPI BOI) (66%, 95% CI: 55, 74); SF-12 Mental Component Scale (MCS) Score (55%, 95% CI: 48, 61), and SF-12 Physical Component Scale (PCS) Score (55%, 95% CI: 48, 61).
Figure 2
Figure 2
Zoster Vaccine Efficacy (%) in Evaluable Cases of Herpes Zoster (n = 857). The figure shows vaccine efficacy for Herpes Zoster Pain and Discomfort Burden of Illness (HZ BOI) Score (19%, 95% CI: 2, 35); Zoster Brief Pain Inventory ADL Burden of Interference (ZBPI BOI) Score (29%, 95% CI: 7, 46), SF-12 Mental Component Scale (MCS) Score (5.2%, 95% CI: −9.4, 17.8), and SF-12 Physical Component Scale (PCS) Score (3.9%, 95% CI: −11, 16).
See this image and copyright information in PMC

Comment in

  • Zoster vaccine in older adults.
    Fried R. Fried R. J Am Geriatr Soc. 2010 Sep;58(9):1799-800. doi: 10.1111/j.1532-5415.2010.03023.x. J Am Geriatr Soc. 2010. PMID: 20863342 No abstract available.

References

    1. Hope-Simpson RE. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9–20. - PMC - PubMed
    1. Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490–497. - PubMed
    1. Chidiac C, Bruxelle J, Daures J-P, et al. Clin Infect Dis. 2001;33:62–69. - PubMed
    1. Katz J, Cooper EM, Walther RR, et al. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39:342–48. - PubMed
    1. Oxman MN, Levin MJ, Johnson GR, Schmader, et al. the Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284. - PubMed

Publication types

MeSH terms

Substances